| Similar Articles |
|---|
 |
The Motley Fool
November 10, 2006 |
Sales Down at King Pharmaceuticals: Fool by Numbers The pharmaceutical released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...   |
The Motley Fool
May 15, 2007
Brian Lawler |
King Fights for Its Empire King Pharmaceuticals announces another good quarter of financial results. Investors should expect more product acquisitions in the coming years. |
The Motley Fool
September 8, 2006
Brian Lawler |
Ligand's Drug Sale For the pharmaceutical's marketed drugs, everything must go. Investors, take note. |
The Motley Fool
October 29, 2004
Bill Mann |
King, Knave, or Village Idiot? Troubled King Pharmaceuticals' latest accounting woes threaten to scuttle its merger with Mylan. |
The Motley Fool
March 1, 2007
Brian Lawler |
King Atop Its Throne After two quarters of middling revenue growth, drugmaker King Pharmaceuticals reported blowout sales and operating cash flow for its fourth quarter. |
The Motley Fool
March 23, 2007
Brian Lawler |
Ligand's Big Payout Ligand decides to return some cash to shareholders. |
The Motley Fool
August 25, 2008
Brian Lawler |
King Triples Down King Pharmaceuticals makes a risky all-in bet on an unproven market. |
The Motley Fool
September 12, 2008
Brian Lawler |
King's Unstoppable Urge to Merge King Pharmaceuticals announces it has increased its offer to acquire Alpharma, and it is now taking that bid directly to the shareholders. |
The Motley Fool
May 28, 2008
Brian Lawler |
King Pays a Modest Ransom King Pharmaceuticals, a prolific acquirer of other companies' drugs, announces that it had painlessly staked its claim to yet another. |
The Motley Fool
October 12, 2010
Travis Hoium |
King Pharmaceuticals Shares Popped: What You Need to Know King Pharmaceuticals shares are up nearly 40% today after it was announced the company would be purchased by Pfizer Inc. |
The Motley Fool
November 10, 2005
W.D. Crotty |
Portfolio Pain Relief Pain Therapeutics announces a significant development deal with King Pharmaceuticals. The company's stock is the largest percentage gainer on the Nasdaq -- up 48.9%. |
The Motley Fool
February 27, 2004
Zeke Ashton |
King Makes a Comeback The love/hate cycle might be ready to shift again for this pharmaceutical. King Pharmaceuticals was once a beloved growth stock. Then it became an unloved drug stock suffering from intensifying competition, a poor acquisition or two, and an ongoing SEC investigation. The stock has started to come back. |
The Motley Fool
August 17, 2006 |
Comparing Companies Evaluate your investment candidates carefully -- here's how to start. |
The Motley Fool
January 26, 2006
Tim Beyers |
A Q2 Sun Burn: Fool by Numbers Sun Microsystems released second-quarter earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights*... |
The Motley Fool
March 3, 2009
Robert Steyer |
Seeking Gain From Pain King Pharmaceuticals tries to remake itself as a pain therapy company. |
The Motley Fool
November 5, 2007
Brian Lawler |
King's Abuse-Resistant Bet King Pharmaceuticals signs a development deal with Acura Pharmaceuticals to produce abuse-resistant painkillers. Investors, take note. |
The Motley Fool
March 1, 2007 |
Profit at King Pharmaceuticals: Fool by Numbers The drugmaker released earnings for the fourth-quarter 2006: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
May 22, 2006
Rich Smith |
Foolish Forecast: Trying on Perry Ellis The clothier reports first-quarter 2007 earnings results tomorrow. Want to know what Wall Street expects to see? Want to know what really matters? Investors, take note. |
The Motley Fool
February 19, 2004
Dave Marino-Nachison |
Jones Apparel Shops for Profits An improved job market and wider operating margins would help the apparel company. |
The Motley Fool
April 28, 2006
Joseph Khattab |
Deckers' Sheepish Quarter: Fool by Numbers Deckers Outdoor released first-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
May 16, 2006
Nathan Parmelee |
Wal-Mart, the Unstoppable: Fool by Numbers The retailer released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
InternetNews
January 13, 2006
Clint Boulton |
SEC is Probing IBM Earnings The Securities and Exchange Commission's investigation into IBM's first-quarter 2005 accounting practices is now official. |
The Motley Fool
April 25, 2006
Rich Smith |
Foolish Forecast: Boeing Approaches Humongous companies like Boeing are tricky beasts to analyze -- simply because there are so many moving parts that it's hard to keep a firm grasp on where the enterprise as a whole is headed. But investors, there's a trend afoot here -- and it looks like a good one. |
The Motley Fool
August 14, 2009
Brian Orelli |
The Real King of the Drug Pushers King Pharma is first up with a tamper-resistant morphine tablet. |
The Motley Fool
November 9, 2006 |
Barr Pharmaceuticals Barrels Ahead: Fool by Numbers The pharmaceutical released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
January 25, 2008
Brian Orelli |
Where the Big Margins Are Drug company investors get to enjoy such high gross margins, but there's generally only so much improvement that a company can make when it starts from such a high point. Take a look at some pharma companies that are succeeding to do just that. |
The Motley Fool
August 11, 2006
Anders Bylund |
Analog Devices Comes Up Short: Fool by Numbers The chip maker released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
Pharmaceutical Executive
June 1, 2006
Sara Calabro |
King Without the Crown While most of pharma tries to convince the world that R&D is the number-one priority, one specialty company, King Pharmaceuticals, boasts that it has no lab. |
The Motley Fool
July 11, 2011 |
Cubist Pharmaceuticals Earnings Preview Cubist Pharmaceuticals will unveil its latest earnings on Thursday. |
The Motley Fool
April 1, 2008
Brian Lawler |
A Competitive Stab at King and Pain A new, dark-horse competitor, privately held Purdue Pharma, arrives to fight King Pharma and Pain Therapeutics. |
The Motley Fool
March 14, 2006
Rich Smith |
Foolish Forecast: Is It HOTT in Here? Investors, focus on inventories and free cash flow. That's where you'll find the first evidence of a turnaround, if one exists. |
The Motley Fool
March 2, 2007
Dan Bloom |
Omnivision Looks Blurry: Fool by Numbers The specialty chip maker released third-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
July 27, 2006
Tim Beyers |
Akamai at It Again: Fool by Numbers The content-delivery king released second-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Checkup... |
The Motley Fool
January 30, 2007
Rick Aristotle Munarriz |
The King Gives Investors Bread and Circus If Burger King keeps growing with its franchisees as happy as The King himself, royalties will be even more generous. Investors, take note. |
Inc.
June 15, 2000
Anne Marie Borrego |
Supplies on Demand Problem: Managing office-supply inventory and purchases
Solution: A Web site that does it all
Payoff: Cost savings, fewer headaches |
The Motley Fool
December 6, 2010
Seth Jayson |
Why the Street Should Love King Pharmaceuticals' Earnings Over the past 12 months, King Pharmaceuticals generated $276.2 million in FCF on net income of $83.9 million. That means it turned 17.6% of its revenue into FCF. That sounds pretty impressive. |
The Motley Fool
December 7, 2007
Brian Lawler |
Pain Continues as Planned Pain Therapeutics reports on a successful phase 3 trial for its lead drug Remoxy. |
The Motley Fool
January 26, 2007
Anders Bylund |
Microsoft Set for a Huge Q3: Fool by Numbers The software king released second-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Management Effectiveness... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
January 21, 2010
Morgan Housel |
What You Should Know About Goldman Sachs' Earnings Digging deeper shows just how important it is to take Goldman's numbers with a grain of salt. |
The Motley Fool
October 5, 2006
Nathan Parmelee |
New York & Co.: Not as Bad as Advertised Comps may have lagged estimates, but reasons for optimism remain. Investors, take note. |
The Motley Fool
September 30, 2008
Brian Orelli |
Pharma, Cash, and You Pharma's been saving for a rainy day, and there's a thunderstorm outside. |
The Motley Fool
March 21, 2011
Jim Royal |
Meet the Cash Kings of Drilling Check out Transocean, the cash king of the drilling sector. |
The Motley Fool
October 31, 2005
Steven Mallas |
Marvel Meets the King Marvel Entertainment and Stephen King hook up for a comic book deal. Marvel shareholders should be excited about this. |
The Motley Fool
June 23, 2008
Brian Lawler |
Wait a Little Longer, Ligand The FDA delays its review of GlaxoSmithKline and partner Ligand Pharmaceutical's blood-disorder drug Promacta. |
The Motley Fool
January 12, 2006
Stephen D. Simpson |
Forest Keeps Reloading An agreement with Mylan Labs gives Forest access to a drug that could be launched in 2006. Investors, take note. |
The Motley Fool
March 29, 2006
Rich Smith |
Foolish Forecast: Best Buy Opens Early Best Buy is expecting to report same-store sales gains of 6% to 7% in the fourth quarter, and "strong" revenue growth overall. In contrast to its customers, Best Buy says it's been keeping tight reins on its own spending. |
The Motley Fool
February 26, 2007 |
Sales Up at Shire Pharmaceuticals: Fool by Numbers The drugmaker released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
PC Magazine
September 21, 2004 |
Age of Empires II: The Age of Kings The king of real-time strategy games has yet to be dethroned. |
Bank Systems & Technology
August 16, 2010
Matt Gunn |
Customer-Centered Banking is the Future, Author Says Brett King discusses his book Bank 2.0 and the future of banking. |
The Motley Fool
June 11, 2008
Brian Lawler |
Pain and King Start the Countdown Who will win the race to get approval of an abuse-deterrent drug, Pain Therapeutics or King Pharmaceuticals? |
